MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue144,27389,258102,756
Cost of Revenue6,91246-
Gross Profit137,36189,212102,756
Operating Expenses
Research Development160,917160,988138,495
Selling General and Administrative80,72957,79530,517
Non Recurring5,8565,8565,856
Total Operating Expenses---
Operating Income or Loss-110,141-129,571-66,256
Income from Continuing Operations
Total Other Income/Expenses Net2681,016927
Earnings Before Interest and Taxes-109,873-128,555-65,329
Interest Expense43,64519,23218,230
Income Before Tax-153,518-147,787-83,559
Income Tax Expense---
Minority Interest-1,53923969
Net Income From Continuing Ops-151,740-147,957-83,291
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-151,740-147,957-83,291
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-151,740-147,957-83,291